- Home
- AVTX
as of 01-07-2026 4:00pm EST
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | WAYNE |
| Market Cap: | 248.3M | IPO Year: | 2015 |
| Target Price: | $32.29 | AVG Volume (30 days): | 314.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.74 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.39 - $20.72 | Next Earning Date: | 11-06-2025 |
| Revenue: | $192,000 | Revenue Growth: | -76.58% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered AVTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Avalo Therapeutics Inc. (AVTX)
Director
Avg Cost/Share
$14.32
Shares
11,367
Total Value
$162,936.78
Owned After
0
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Goldman Jonathan | AVTX | Director | Nov 14, 2025 | Sell | $14.32 | 11,367 | $162,936.78 | 0 |
Compare AVTX vs Leading Stocks
See how AVTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AVTX Avalo Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.